Twenty-one children with achondroplasia took two prodrugs a week instead of one, and grew 8.7 centimeters a year. Matched controls on the single drug grew 5.95.
The proof-of-concept Phase 2 COACH trial ↗, published online May 18 in the European Journal of Endocrinology, paired Ascendis Pharma's two prodrug peptides in kids aged 2 to 11. Navepegritide is a long-acting prodrug of C-type natriuretic peptide (CNP), the endogenous growth-plate signal that the FGFR3 gain-of-function mutation in achondroplasia partially blocks. Lonapegsomatropin is a prodrug of recombinant human growth hormone (somatropin), already FDA-approved in pediatric growth hormone deficiency as SkyTrofa. The hypothesis the trial was built to test was straightforward. Releasing the prehypertrophic block in the growth plate with CNP should let GH actually do the work it cannot do on the achondroplastic plate alone.
The proof-of-concept worked. Among the 12 children who had never been on a growth-promoting therapy before, the combination produced an annualized growth velocity of 8.69 cm per year over 52 weeks, compared with 5.95 cm per year in matched controls on navepegritide monotherapy from the earlier ApproaCH trial. The 2.74 cm per year difference was statistically significant (p less than 0.0001). Measured against the children's own pre-treatment baselines, the combination boost was 3.89 cm per year (p equals 0.0015), roughly doubling the typical-growth-velocity expectation for an achondroplastic child in that age range.
The second cohort tells the more interesting story. Nine children had already been on navepegritide monotherapy for more than a year when they added lonapegsomatropin. Their growth velocity jumped 3.28 cm per year (p less than 0.0001) on top of what monotherapy had already established. They landed at 8.42 cm per year, essentially the same place as the treatment-naive group. Two cohorts that started a full year of monotherapy apart converged on the same outcome once the GH prodrug was added.
What the picture looks like next to vosoritide
For context on what 8.7 cm a year means in achondroplasia, BioMarin's vosoritide (Voxzogo), the first FDA-approved CNP analog and the field's current baseline, runs about 1.4 to 1.5 cm a year above untreated growth velocity in the registration trials. The COACH combination ran about 3.9 cm a year above its own pretreatment baseline in the treatment-naive arm. The catch is the comparison is not apples to apples. COACH is single-arm against a historical control from a different trial, the population is 12 kids, and the follow-up is a year. Vosoritide has multi-year extension data in hundreds of patients. The honest read is that the combination signal is large enough to justify a powered Phase 3 against a real-time monotherapy arm, not that the question is settled.
The body-proportionality readout is harder to dismiss. Arm span gained 9.4 cm in the treatment-naive cohort and 7.9 cm in the navepegritide-experienced cohort. Disproportionately short arms relative to torso length are one of the functional signatures of achondroplasia, and the disproportion is a clinically meaningful disability axis (reaching the top of one's own head is part of activities of daily living). A growth-velocity gain that pulls torso, arms, and legs together is mechanistically more believable than one that lifts the standing-height number without changing the proportions, because the latter is at least partially a torso-only effect.
What the news is
The news is that two peptide prodrugs from the same company, each individually unremarkable as a growth-promoting agent in this indication (navepegritide is approved nowhere yet, lonapegsomatropin alone does very little for achondroplasia), produced a combined effect that is the largest single readout in the achondroplasia therapy literature to date. Two prodrugs solving one problem by hitting two complementary axes of the growth plate is a mechanistic argument that is going to get tested in other dwarfism phenotypes (hypochondroplasia, the SHOX-deficiency disorders) and probably in idiopathic short stature. Ascendis will need a Phase 3 powered against navepegritide alone and ideally against vosoritide alone, with intent-to-treat analysis and pre-specified body-proportionality endpoints. The companies are racing, and the molecule that owns the proportionality endpoint will own the next decade of pediatric growth-plate medicine.
The platform connection is thin and that is fine. Neither prodrug is currently on a peptidemodel card, the receptors involved (NPR-B for CNP, growth hormone receptor for somatropin) are not on the news-tag target list, and the FGFR3 disease axis sits outside the GLP-1 and MASLD reporting that has dominated this section for the past two weeks. That is part of why the piece is worth running. The achondroplasia growth-plate story is a reminder that peptide therapeutics are a real category outside the GLP-1 receptor agonist hype cycle, and that a 21-patient Phase 2 from a mid-cap Danish biotech can carry a genuine pharmacological lesson.